PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 25, 2005--AVI BioPharma, Inc. (Nasdaq: AVII), today announced publication of preclinical research in the Journal of Virology and the Journal of General Virology. The results detail findings from studies of AVI’s NEUGENE(R) antisense agents in cell models of dengue virus and equine arteritis virus.
